This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ResMed's (RMD) Q2 Earnings Beat Estimates, Margins Falls
by Zacks Equity Research
ResMed's (RMD) mask sales growth was strong across the globe, reflecting a post-COVID pandemic awareness about the importance and need for respiratory hygiene and respiratory health.
Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and COMPASS Pathways PLC Sponsored ADR (CMPS) have performed compared to their sector so far this year.
McKesson (MCK) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
What's in the Cards for Illumina (ILMN) in Q4 Earnings?
by Zacks Equity Research
Negative foreign exchange impact and consumables inventory deleveraging are expected to have affected Illumina's (ILMN) top line during the fourth quarter.
CVS Health (CVS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) digital capabilities are expected to have driven consumer engagement across all CVS Health businesses in Q4.
Cardinal Health (CAH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
STERIS (STE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) hospital capital spending is expected to have remained robust in Q3, as evident from the healthcare backlog's recent trend.
Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have witnessed continued recovery in its legacy business in the fourth quarter, despite the choppy market situation.
Abbott's (ABT) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
The downside can be attributed to a manufacturing disruption during 2022 of certain infant formula products at Abbott's (ABT) Sturgis, MI facility.
NextGen (NXGN) Q3 Earnings Fall Shy of Estimates, Revenues Top
by Zacks Equity Research
NextGen's (NXGN) third-quarter fiscal 2023 results reflect strength in its Recurring revenues.
Here's Why You Should Retain DaVita (DVA) Stock for Now
by Zacks Equity Research
Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.
CVS Health (CVS) to Expand Health Care Access With New Pact
by Zacks Equity Research
CVS Health's (CVS) recent collaboration establishes new Accountable Care that focuses on health equity, coordinated care and enhanced access.
Quest Diagnostics (DGX) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Quest Diagnostics (DGX) ramps up investments to accelerate growth in the base business, particularly in advanced diagnostics and direct-to-consumer testing.
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) fourth-quarter results are likely to reflect its strong segmental performances. However, rising costs are likely to have continued to have hurt margins during the quarter.
QIAGEN's (QGEN) New Launch to Enhance Clinical Lab Workflow
by Zacks Equity Research
QIAGEN's (QGEN) latest launch is expected to aid the clinical diagnostics labs to boost their performance.
Here's Why You Should Retain Veeva Systems (VEEV) Stock for Now
by Zacks Equity Research
Veeva Systems' (VEEV) slew of product launches raises optimism about the stock.
Abbott's (ABT) New FDA Approval to Improve Patient Outcome
by Zacks Equity Research
Abbott's (ABT) latest regulatory clearance is expected to improve the treatment of high-risk patients with aortic stenosis.
Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe
by Zacks Equity Research
Walgreens Boots (WBA) continues to progress in transforming the pharmacy business and the method of delivering healthcare through physical stores and digital channels.
What's in Store for Thermo Fisher (TMO) in Q4 Earnings?
by Zacks Equity Research
The industrywide trend of record-level inflation, supply issues and staffing shortages are expected to have deterred growth in several areas of Thermo Fisher's (TMO) business in Q4.
IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) CAG premium instrument placements are expected to have recorded significant growth in Q4 owing to continued rise in Catalyst and premium hematology placements.
Cardinal Health, Inc. (CAH) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Cardinal (CAH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Charles River's (CRL) New CDMO Tie-Up to Boost Clinical Trials
by Zacks Equity Research
Charles River's (CRL) latest partnership is expected to bring a potentially curative therapy, RZ-001, to HCC patients.